SCHEMBL2025367

SCHEMBL2025367

O=C1c2ccc(-c3cccnc3)cc2CN1Cc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DHPS P49366 3/20 0.53
HDAC1 Q13547 3/20 0.50
HDAC4 P56524 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
TNIK Q9UKE5 2/20 0.49
CYP11B1 P15538 3/20 0.45
CYP11B2 P19099 3/20 0.45
CYP1A2 P05177 1/20 0.45
CHRM5 P08912 1/20 0.43
GRM2 Q14416 1/20 0.43
ADAM17 P78536 1/20 0.42
TDP2 O95551 1/20 0.42
PRMT5 O14744 1/20 0.42
WDR77 Q9BQA1 1/20 0.42
PSMB5 P28074 1/20 0.41
TRPV6 Q9H1D0 1/20 0.41
HDAC7 Q8WUI4 1/20 0.40
BRD4 O60885 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2026710 0.89 HDAC1 (0.47) DHPSHDAC1HDAC4HDAC6TNIK
SCHEMBL2048064 0.85 DHPS (0.55) DHPSHDAC1HDAC4HDAC6TNIK
SCHEMBL19967154 0.85 DHPS (0.52) DHPSHDAC1HDAC4HDAC6TNIK
SCHEMBL2021064 0.84 DHPS (0.47) DHPSHDAC1HDAC4HDAC6TNIK
SCHEMBL2024513 0.83 DHPS (0.46) DHPSHDAC1HDAC4HDAC6TNIK
SCHEMBL2025909 0.82 TNIK (0.46) DHPSHDAC1HDAC4HDAC6TNIK
SCHEMBL2028118 0.79 GRM2 (0.43) DHPSHDAC1HDAC4HDAC6TNIK
SCHEMBL9148456 0.79 CYP11B2 (0.47) DHPSCYP11B1CYP11B2TRPV6
SCHEMBL2025564 0.78 MEN1 (0.44) HDAC1HDAC4HDAC6TNIKCHRM5
SCHEMBL2028744 0.77 KMT2A (0.58) HDAC1HDAC4HDAC6HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2357169-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators AstraZeneca AB (SE) 2011-08-17 EP disclosed
EP-2357169-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators AstraZeneca AB (SE) 2011-08-17 EP disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM3 DHPS 2532/4885HDAC1 2500/4885HDAC4 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.